GE

229.94

-1.55%↓

RTX

133.99

-0.7%↓

CAT

344.89

+0.69%↑

BA

203.21

+0.01%↑

HON

223.26

+0.88%↑

GE

229.94

-1.55%↓

RTX

133.99

-0.7%↓

CAT

344.89

+0.69%↑

BA

203.21

+0.01%↑

HON

223.26

+0.88%↑

GE

229.94

-1.55%↓

RTX

133.99

-0.7%↓

CAT

344.89

+0.69%↑

BA

203.21

+0.01%↑

HON

223.26

+0.88%↑

GE

229.94

-1.55%↓

RTX

133.99

-0.7%↓

CAT

344.89

+0.69%↑

BA

203.21

+0.01%↑

HON

223.26

+0.88%↑

GE

229.94

-1.55%↓

RTX

133.99

-0.7%↓

CAT

344.89

+0.69%↑

BA

203.21

+0.01%↑

HON

223.26

+0.88%↑

Search

Ocugen Inc

Suletud

0.9 8.43

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.78

Max

0.94

Põhinäitajad

By Trading Economics

Sissetulek

-1.5M

-15M

Müük

717K

1.5M

Aktsiakasum

-0.05

Kasumimarginaal

-1,036.462

Töötajad

95

EBITDA

-1.3M

-15M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+662.65% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

7. aug 2025

Turustatistika

By TradingEconomics

Turukapital

20M

225M

Eelmine avamishind

-7.53

Eelmine sulgemishind

0.9

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

Ocugen Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

22. mai 2025, 23:48 UTC

Kuumad aktsiad

Stocks to Watch: Deckers Outdoor, Intuit, Ross Stores, Lightbridge, NuScale Power, Centrus Energy

22. mai 2025, 23:07 UTC

Peamised uudised

Fortescue Energy CEO to Resign in Executive Overhaul

22. mai 2025, 23:03 UTC

Suurimad hinnamuutused turgudel

Nuclear-Industry Stocks Get Boost After Report Says Trump Will Sign Orders to Jumpstart Field

22. mai 2025, 23:59 UTC

Market Talk

Gold Edges Higher, Supported by Lingering Worries Over U.S. Deficits -- Market Talk

22. mai 2025, 23:45 UTC

Market Talk

Nikkei May Trade in Range as Uncertainty Over Tariffs Continues -- Market Talk

22. mai 2025, 23:45 UTC

Market Talk

Global Equities Roundup: Market Talk

22. mai 2025, 23:23 UTC

Market Talk

Global Energy Roundup: Market Talk

22. mai 2025, 23:23 UTC

Market Talk

Fortescue Iron Bridge Delay Disappoints; Executive Changes Welcomed -- Market Talk

22. mai 2025, 23:12 UTC

Peamised uudised

Supreme Court Lets Trump Fire Agency Officials, but Moves to Protect Fed -- WSJ

22. mai 2025, 21:54 UTC

Peamised uudised

Global Finance Officials Gloss Over Trade Tensions At G-7 Summit -- WSJ

22. mai 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

22. mai 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

22. mai 2025, 20:46 UTC

Omandamised, ülevõtmised, äriostud

Alcon and Lensar Receive FTC Requests for Additional Information About Merger

22. mai 2025, 20:39 UTC

Tulu

Tesla's Emissions Credits Are at Risk After Senate's California Vote -- Barrons.com

22. mai 2025, 20:36 UTC

Peamised uudised

Antitrust Cops Say BlackRock, Other Fund Giants May Have Harmed Energy Competition -- 4th Update

22. mai 2025, 20:36 UTC

Peamised uudised
Tulu

Workday Logs Higher 1Q Revenue, Backs Outlook; Initiates $1B Buyback Program

22. mai 2025, 20:32 UTC

Peamised uudised
Tulu

Intuit Stock Rises After Earnings Grew More than Expected In Latest Tax Season -- Barrons.com

22. mai 2025, 20:27 UTC

Peamised uudised

Trump's 'Big, Beautiful Bill' Heads to Senate, Where New Fights Loom -- WSJ

22. mai 2025, 20:20 UTC

Peamised uudised

Bond Market Shows Signs of Stabilizing; Nasdaq Rises -- WSJ

22. mai 2025, 20:17 UTC

Peamised uudised

The Deficit Is Unsettling Bond Traders. Here's How That Affects the Economy. -- 2nd Update

22. mai 2025, 20:16 UTC

Tulu

Intchains Group 1Q Rev $18.2M >ICG

22. mai 2025, 20:15 UTC

Peamised uudised

Bond Market Shows Signs of Stabilizing; Nasdaq Rises -- WSJ

22. mai 2025, 20:08 UTC

Peamised uudised
Tulu

Intuit Stock Rises After Earnings Grew More than Expected In Latest Tax Season -- Barrons.com

22. mai 2025, 20:05 UTC

Peamised uudised

Intuit Seeing Stable Environment for Consumers, Businesses While Tariffs Play Out

22. mai 2025, 20:04 UTC

Tulu

Workday Sees FY26 Subscription Revenue $8.8B >WDAY

22. mai 2025, 20:04 UTC

Tulu

Workday Sees 2Q Subscription Revenue $2.16B >WDAY

22. mai 2025, 20:01 UTC

Tulu

Intuit Sees FY25 EPS $13.19-EPS $12.24 >INTU

22. mai 2025, 20:01 UTC

Tulu

Workday 1Q Net $68M >WDAY

22. mai 2025, 20:01 UTC

Tulu

Workday 1Q EPS 25c >WDAY

22. mai 2025, 20:01 UTC

Tulu

Workday 1Q Adj EPS $2.23 >WDAY

Võrdlus sarnastega

Hinnamuutus

Ocugen Inc Prognoos

Hinnasiht

By TipRanks

662.65% tõus

12 kuu keskmine prognoos

Keskmine 6.33 USD  662.65%

Kõrge 8 USD

Madal 4 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Ocugen Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

3

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

0.6818 / 0.74Toetus ja vastupanu

Lühikene perspektiiv

Strong Bearish Evidence

Keskpikk perspektiiv

Strong Bullish Evidence

Pikk perspektiiv

No Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.